The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index; 4 of the 27 sources its claims cite were checked for support.
Description of a Large Family with Autosomal Dominant Hypercholesterolemia Associated with the APOE p.Leu167del Mutation
Open accessAbstract
Apolipoprotein (apo) E mutants are associated with type III hyperlipoproteinemia characterized by high cholesterol and triglycerides levels. Autosomal dominant hypercholesterolemia (ADH), due to the mutations in the LDLR, APOB, or PCSK9 genes, is characterized by an isolated elevation of cholesterol due to the high levels of low-density lipoproteins (LDLs). We now report an exceptionally large family including 14 members with ADH. Through genome-wide mapping, analysis of regional/functional candidate genes, and whole exome sequencing, we identified a mutation in the APOE gene, c.500_502delTCC/p.Leu167del, previously reported associated with sea-blue histiocytosis and familial combined hyperlipidemia. We confirmed the involvement of the APOE p.Leu167del in ADH, with (1) a predicted destabilization of an alpha-helix in the binding domain, (2) a decreased apo E level in LDLs, and (3) a decreased catabolism of LDLs. Our results show that mutations in the APOE gene can be associated with bona fide ADH.
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
This paper reports an exceptionally large French family with autosomal dominant hypercholesterolemia (ADH) in which linkage mapping and exome sequencing identified the APOE p.Leu167del mutation as the likely cause. The authors conclude that APOE mutations can be associated with bona fide ADH and that APOE screening is warranted alongside LDLR, APOB, and PCSK9 in ADH molecular diagnosis.
Key findings
- In the HC126 family, genome-wide linkage gave a maximum LOD score of 2.55 (θ=0) at rs718087 on chromosome 19; multipoint analysis at 19q13.31–13.32 gave a maximum LOD score of 3.15 between rs1988065 and rs3513657 (19:43,374,601–45,439,163).
- The APOE c.500_502delTCC (p.Leu167del) mutation was identified and was not detected in over 220 controls. Additional APOE variants p.Arg269Gly and p.Arg235Trp were found in non-LDLR/APOB/PCSK9 probands and were absent in over 500 French controls.
- Two p.Leu167del carriers had total apo E levels of 4.09 mg/dL and 4.03 mg/dL, both within the normal range (2.30–6.30 mg/dL); apo E distribution showed a higher proportion in HDL (77% vs 63–69%) and a lower proportion in LDL (12% vs 18–25%).
- In one carrier after a 2-month washout, lipid values were triglycerides 3.7, total cholesterol 10.5, LDL-cholesterol 8.1, and HDL-cholesterol 0.7 mmol/L; LDL kinetics resembled those of familial hypercholesterolemia patients, with an increased LDL pool due to increased LDL production and decreased LDL catabolism. No splenomegaly or thrombocytopenia was present in the 12 APOE p.Leu167del carriers of HC126 nor in the proband of HC512.
Methods
- ADH families were recruited by the French National Research Network on Hypercholesterolemia; the HC126 family was initiated through proband II-2 and expanded to 27 individuals over 3 generations, exploring 23 meioses. Inclusion criteria included total and LDL-cholesterol above the 95th percentile, triglycerides below 1.5 mmol/L, and personal and/or documented familial xanthomas and/or early coronary artery disease.
- The study combined genome-wide linkage mapping (with 100,000 simulations; av.ELOD 2.1, max.ELOD 4.8), regional microsatellite/multipoint analysis, candidate gene sequencing, and whole exome sequencing in three affected members (III-2, III-7, III-8).
- APOE p.Leu167del was screened by direct fluorescent PCR in controls, and the APOE gene was sequenced in 153 non-LDLR/APOB/PCSK9 probands (55 French ADH and 98 Norwegian hyperlipidemics). The authors also performed homology modeling, measured apo E levels and lipoprotein distribution, and conducted in vivo apo B-100 kinetic studies in one patient after washout.
Limitations
- Stated: the apo E distribution data need confirmation because they are based on only two patients, including one under lipid-lowering therapy; the kinetic data need confirmation because they are based on only one patient.
- Stated: a LDL receptor-binding defect could not be directly excluded, and a prior in vitro competitive binding test with apo E from a heterozygous p.Leu167del carrier showed no significant binding defect, so the effect of the deleted mutant alone could not be observed.
- Evident: the small number of mutation carriers limits biochemical and kinetic conclusions; the family also includes possible phenocopies (I-3 and II-14) and an unclassified patient (II-5), suggesting another lipid abnormality in the family remains unidentified.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
23 Own result · 19 Own interpretation · 15 No full text of the sources · 4 Sources not found · 3 Own method · 2 Partly supported · 1 Supported so far · 1 Not supported · 1 Not checked yet · accuracy not yet measured
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Among 9 non-LDLR/-APOB/-PCSK9/-HCHOLA4 families we have identified, one was large enough to enable genome wide mapping of a new ADH gene (Marques-Pinheiro A et al. 2010).”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
What the sources say
- Disputedcites Marques-Pinheiro A et al. 2010 sourceExperimental — accuracy not yet measured
The Abstract and Linkage analysis section distinguish the large family used to map HCHOLA4 from the nine families that excluded linkage to that locus. The paper therefore does not place the genome-mapped family among those nine; it says the opposite. Our copy provides no page numbers for these passages. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
plaincorrelationalSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“at least 19% of ADH families in which the disease is not associated with a mutation within one of these three genes (Marduel M et al. 2010).”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
What the sources say
- Partly supportedcites Marduel M et al. 2010 sourceExperimental — accuracy not yet measured
The Results and Discussion report that no mutation in LDLR, APOB or PCSK9 was identified in 258 of 1,358 French ADH probands (19.0%). This supports the percentage for that cohort, but the claim extends it to ADH families generally and treats an unidentified mutation as evidence that no mutation in those genes is associated with their disease. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Regional haplotype construction allowed the identification of a common region for affected members from D19S417 to D19S908 (Figure 1A).”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
plaincorrelationaln = 27- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Phenotypically unclassified patient II-5 did not carry the familial-disease haplotype”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
plainSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Through genome wide mapping, analysis of regional/functional candidate genes and whole exome sequencing, we identified a mutation in the APOE gene, p.Leu167del”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“a decreased catabolism of LDL”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The p.Leu167del variation interrupts one α helix in a group of four helices stabilized by a leucine zipper.”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“the c.500_502delTCC (p.Leu167del, formerly called Δ149Leu) variation in the APOE gene (RefSeq NM_000041.2) was found”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
plainn = 2- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“a decreased apo E level in LDL”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“After this period, the lipid values for this patient were: 3.7, 10.5, 8.1 and 0.7 mmol/L for triglycerids, total-, LDL- and HDL-cholesterol respectively.”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
plainSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The two missense variations, p.Arg269Gly and p.Arg235Trp, were absent in over 500 French controls, indicating that they are not frequent.”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
hedgedn = 500- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Total apo E levels were measured for p.Leu167del carriers, HC126-II-2 (apo E = 4.09 mg/dL, under rosuvastatin), HC126-III-2 (apo E = 4.03 mg/dL), and were both in the normal range (2.30–6.30 mg/dL in French controls).”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
plainn = 2- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We now report an exceptionally large family including 14 members with ADH.”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The genome-wide scan provided a maximum LOD score of 2.55 (θ=0) for rs718087 on chromosome 19 (Supp. Table S1).”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
plaincorrelationaln = 27- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Within the French ADH probands, the p.Leu167del variation, and p.Arg269Gly (c.805C>G) were found for family HC512 and HC298, respectively”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
plaincorrelationalSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Four variants were found, the c.437G>A (p.Arg146Gln) in the CCDC123 gene, the c.1151A>G (p.Gln384Arg) in the RHPN2 gene, the c.657G>C (p.Asn219Lys) in the CEACAM8 gene and the c.500_502delTCC (p.Leu167del) in the APOE gene.”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The 19q13.31–13.32 multipoint analysis gave a maximum LOD score of 3.15 between rs1988065 and rs3513657 (19:43,374,601–45,439,163) (Supp. Table S1, Supp. Figure S1).”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
plaincorrelationaln = 27- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Within the Norwegian hyperlipidemic cohort, p.Arg235Trp (c.703C>T) was found in a 56 years old man with 9.4, 2.7, 6.4 and 1.8 mmol/L of total cholesterol, triglycerides, LDL and HDL, respectively, and the E3E4 apo E isoformes (Supp. Figure S2).”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
plainSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Within the French ADH probands, the p.Leu167del variation, and p.Arg269Gly (c.805C>G) were found for family HC512 and HC298, respectively”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
plaincorrelationalSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Finally, there is an increased LDL pool due to the combination of this abnormal metabolic cascade and decreased LDL catabolism.”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
plaindirectSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The identification of these other APOE mutations for ADH probands is a major finding that confirms the involvement of apo E alterations in the pathogenesis of ADH.”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The hyperLDLemia observed in the HC126 family would thus reveal the pure effect of the p.Leu167del mutation.”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
hedgeddirectSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“However, their proband was heterozygous for apo E p.Leu167del, thus, the effect of the deleted mutant could not be observed alone.”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
plaindirectSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Despite the decreased conversion of VLDL to IDL, the very important VLDL production implies that a higher than normal proportion of lipoprotein follows the metabolic cascade leading to an increased apo B-100 flux into the next lipoprotein fractions.”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
plaindirectSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“a predicted destabilization of an alpha-helix in the binding domain”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“However, tissue expression profile and reports of alterations of this gene’s expression in acute lymphoblastic leukemias (Lasa A et al. 2008) excluded this variant as a possible ADH disease-causing mutation.”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
What the sources say
- Not checked — no full text of the sourcecites Lasa A et al. 2008 source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Our results show that mutations in the APOE gene can be associated with bona fide ADH.”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“This overlap between the FCHL and ADH phenotype has also been reported for mutations in the LDLR gene (Civiera et al. 2008).”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
What the sources say
- Not matchedcites Civiera et al. 2008
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
In the paper
“Nguyen et al. performed a competitive receptor binding test in vitro with apo E isolated from VLDL of one p.Leu167del carrier and observed no significant binding defect.”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
What the sources say
- Not checked — no full text of the sourcecites Nguyen TT et al. 2000 source
plainSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Disruption of one helix in the group very probably alters the interaction with the three others.”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Thus, a LDL receptor-binding defect could not directly be excluded under the hypothesis of a compensatory increased activity of the normal apoE in the presence of the deleted mutant.”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
hedgedSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- The authors state this as an assumption: A compensatory increased activity of the normal apoE in the presence of the deleted mutant could mask a LDL receptor-binding defect.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“One hundred thousand simulations were performed to evaluate the power and the relevance of a genome wide linkage scan in HC126. The av.ELOD score was 2.1, with a max.ELOD score of 4.8, therefore indicating that the statistically significant threshold of 3 could be reached.”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
hedgedSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We confirmed the involvement of the APOE p.Leu167del in ADH”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“Hypertriglyceridemia can sometimes be observed in ADH subjects, mainly because of the many common genetic and environmental factors contributing to triglyceride elevation (Talmud PJ 2001).”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
What the sources say
- Not checked — no full text of the sourcecites Talmud PJ 2001 source
plainconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Finally, the p.Leu167del in the APOE gene was the only possible disease-causing mutation within the candidate locus.”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“It is thus very likely that a deletion of an amino acid in this motif would alter the general structure of this highly conserved part of apo E.”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Probably not a substantial claim. 16
- It may state two separate claims as one. 24
- The quote only partly states this claim. 1
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“new ADH loci were recently mapped at 16q22.1, HCHOLA4 (Marques-Pinheiro A et al. 2010), and 8q24.22 (Cenarro A et al. 2011).”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
What the sources say
- Supportedcites Marques-Pinheiro A et al. 2010 source
The Discussion states that a genome-wide scan in a large French family mapped a fourth ADH locus at 16q22.1. The Introduction names that locus HCHOLA4. The 8q24.22 locus is attributed to a different citation in the citing sentence, so it is not part of this verdict. (LLM, conf=0.94)
- Not checked — no full text of the sourcecites Cenarro A et al. 2011 source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may state two separate claims as one.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“VLDL and IDL kinetic parameters were in accordance with the high triglyceride level only observed for this measurement, and never before in this patient, showing similarities with a type III hyperlipoproteinemia (E2E2 genotype) such as the dramatically increased VLDL and IDL pool due to a decreased conversion rate (Ooi EM et al. 2010).”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
What the sources say
- Partly supportedcites Ooi EM et al. 2010 sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
plaindirectSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Leu167 of apoE is not a conserved amino acid, but is the fourth residue in a 6 amino acid motif of which positions 1, 2, 3 and 6 are very well conserved from Xenopus tropicalis to Homo sapiens (Supp. Figure S3).”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No splenomegaly or thrombocytopenia were present in the 12 APOE p.Leu167del carriers of the HC126 family nor in the proband of HC512 indicating that these subjects did not present the sea-blue histiocytosis disease.”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“The APOE p.Leu167del was not detected in over 220 controls, in agreement with Faivre et al. who had investigated 50 French controls, and indicating that this apo E variation is not a frequent polymorphism.”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
What the sources say
- Not checked — no full text of the sourcecites Faivre L et al. 2005 source
hedgedn = 220- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“The two first variants were shown to be frequent genomic variants (//snp.gs.washington.edu/EVS/, //www.1000genomes.org), excluding them from being a possible disease-causing mutation.”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The recruitment of the HC126 family was initiated through the female proband II-2, and expanded to 27 individuals over 3 generations, thus exploring 23 meioses (Figure 1A).”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
plainn = 27- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Interestingly, the increased VLDL and IDL pool for the HC126 patient was also due to an increased production rate, that was not observed for E2E2 patients, but already reported for patients carrying a PCSK9 gene mutation (Ouguerram K et al. 2003).”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
What the sources say
- Not checked — no full text of the sourcecites Ouguerram K et al. 2003 source
plaindirectSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Apo E distribution in each lipoprotein fraction showed a higher proportion in HDL (77% vs 63–69%), and a lower proportion in LDL (12% vs 18–25%) (Supp. Table S3).”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
plaincorrelationaln = 2- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“LDL kinetic parameters were similar to those from FH patients (mutation in the LDLR gene) with an increased LDL pool, which was the consequence of both an increase in LDL production rate and a decrease in LDL catabolism (Table 1).”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
plaindirectSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The CEACAM8 variant is rare, 3/10755 in the Exome Variant Server and not reported by the “1000 genome” project.”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“rare apo E mutants have been described associated with type III hyperlipoproteinemia or lipoprotein glomerulopathy (OMIM +611771).”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
What the sources say
- Not matchedcites OMIM +611771
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
- Not matched
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“previously reported associated with sea-blue histiocytosis and familial combined hyperlipidemia”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
What the sources say
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“Apo E2 isoform is associated with lower LDL cholesterol, except for 5% of E2/E2 carriers who develop type III hyperlipoproteinemia (OMIM +107741)”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
What the sources say
- Not matchedcites OMIM +107741
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
- Not matched
In the paper
“ADH is genetically heterogeneous and associated with mutations in the well-known LDLR (low density lipoprotein receptor) (FH, OMIM #606945), APOB (apolipoprotein B-100) (FDB, OMIM # 144010) and PCSK9 (Proprotein Convertase Subtilisin/Kexin type 9, Abifadel M et al. 2003) genes.”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
What the sources say
- Not checked — no full text of the sourcecites Abifadel M et al. 2003 source
boostedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Accordingly, IDL production is increased and, combined to the low IDL catabolism, leads to an increased LDL production.”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
plaindirectSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“The APOE p.Leu167del mutation was reported in subjects with familial combined hyperlipidemia (FCHL, type III dyslipoproteinemia) (Solanas-Barca M et al. 2012) and in the HC126 family reported here with a bona fide ADH.”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
What the sources say
- Not checked — no full text of the sourcecites Solanas-Barca M et al. 2012 source
plaincorrelationalSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Apo E4 isoform is associated with elevated total and LDL-cholesterol levels, due to the higher affinity of apo E4 for VLDL and LDL”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
What the sources say
- Not checked — no full text of the sourcecites Hatters DM et al. 2006 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“a few rare apo E variants (p.Glu21Lys, p.Pro102Arg and, p.Leu270Glu) have been observed in probands with hyperLDLemia (type IIa hyperlipoproteinemia), but none co-segregated with hyperLDLemia in the families (Wardell MR et al. 1991, van den Maagdenberg AM et al. 1993).”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
What the sources say
- Not checked — no full text of the sourcecites Wardell MR et al. 1991 source
- Not checked — no full text of the sourcecites van den Maagdenberg AM et al. 1993
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“However, these data need to be confirmed because they are based on the study of only two patients, including one under a lipid lowering therapy.”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
plainn = 2- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The other mutations, p.Arg235Trp and p.Arg269Gly, are at the origin of a loss of charge in the first and second α helices of the C-terminal domain that very probably change each helix’s properties, interaction with lipoproteins, and receptor binding.”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“However, these data need to be confirmed because they are based on the study of only one patient.”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
plainSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may state two separate claims as one.
In the paper
“The p.Arg269Gly apo E mutant has been previously reported in a proband with type IIb hyperlipoproteinemia, differing from ADH by elevated plasma triglyceride levels (Wardell MR et al. 1991).”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
What the sources say
- Not checked — no full text of the sourcecites Wardell MR et al. 1991 source
plaincorrelationalSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“Whereas apo E3 and apo E4 bind with similarly high affinity to the LDL receptor, the binding of apo E2 is 50- to 100- times weaker (Weisgraber KH et al. 1982).”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
What the sources say
- Not checked — no full text of the sourcecites Weisgraber KH et al. 1982 source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“as well as the two affected members I-3 and II-14 who highly probably display a phenocopy form of ADH”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one. The quote only partly states this claim.
In the paper
“The APOE gene accounts for a significant fraction of the variation in plasma cholesterol levels (Eichner JE et al. 2002).”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
What the sources say
- Not checked — no full text of the sourcecites Eichner JE et al. 2002 source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Altogether, both hypotheses are in agreement with a decreased catabolism of LDL bearing apo E p.Leu167del and thus explaining the hyperLDLemia observed in the family.”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
plaindirectSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Mutations in the LDLR or APOE gene may amplify the effect of these factors, and thus, according to the number or the nature of these factors, could be associated with an overlapping phenotype between FCHL and ADH.”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“LDL kinetic parameters of apo E mutant carrier were similar to those from FH patients strengthening the very probable effect of LDL bearing an apo E mutant on their catabolism.”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
boostedconditionalSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Autosomal Dominant Hypercholesterolemia (ADH), due to mutations in the LDLR, APOB or PCSK9 genes, is characterized by an isolated elevation of cholesterol due to high levels of low-density lipoproteins (LDL).”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
What the sources say
- Not checked — no full text of the sourcecites Abifadel M et al. 2003 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
In the paper
“The APOE p.Leu167del mutation was reported to be associated with sea-blue histiocytosis (OMIM #26960)”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
What the sources say
- Not matchedcites OMIM #26960
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
- Not matched
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The electrostatic surface charges are altered in apo E p.Leu167del, that also likely influences interaction with lipids and affinity of apo E to its receptors.”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“The APOE p.Leu167del mutation was also reported in subjects with familial combined hyperlipidemia (FCHL, type III dyslipoproteinemia) (Solanas-Barca M et al. 2012).”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
What the sources say
- Not checked — no full text of the sourcecites Solanas-Barca M et al. 2012 source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
The authors state this as an assumption.
A compensatory increased activity of the normal apoE in the presence of the deleted mutant could mask a LDL receptor-binding defect.
“under the hypothesis of a compensatory increased activity of the normal apoE in the presence of the deleted mutant”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“FH due to APOE deficiency is recessively inherited, as in APOE-deficient homozygotes, but APOE variants diagnosed as ADH have also been reported29).”
From Impact of Apolipoprotein E Variants: A Review of Naturally Occurring Variants and Clinical Features (2025) · cites this paper as [29]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Subsequently, whole-exome sequencing and functional analysis of large French and Italian families containing many FH patients revealed that APOE p.Leu167del (Leu149del) is involved in ADH29, 57, 118).”
From Impact of Apolipoprotein E Variants: A Review of Naturally Occurring Variants and Clinical Features (2025) · cites this paper as [29]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Within a Norwegian hyperlipidemic cohort, APOE p.Arg235Trp (Arg217Trp) was found in a 56-year-old man with total cholesterol, triglyceride, LDL, and HDL levels of 363, 239, 247, and 69.6 mg/dL, respectively, along with the apoE3/E4 isoforms29).”
From Impact of Apolipoprotein E Variants: A Review of Naturally Occurring Variants and Clinical Features (2025) · cites this paper as [29]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Of the 11 cases of APOE deficiency with reported mutation sites, four were homozygotes and seven were compound heterozygotes or heterozygotes27, 29-40).”
From Impact of Apolipoprotein E Variants: A Review of Naturally Occurring Variants and Clinical Features (2025) · cites this paper as [29]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > Abstract
“8q24.22 (Cenarro A et al. 2011)”
§ Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation > References
“4. Cenarro A Garcia-Otin AL Tejedor MT Solanas M Jarauta E Junquera C Ros E Mozas P Puzo J Pocovi M Civeira F 2010 A presumptive new locus for autosomal dominant hypercholesterolemia mapping to 8q24.22 Clin Genet 20629670”
Citations
Cites
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
Abifadel, M., Varret, M., Rabès, J.-P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D., et al. (2003) · Nature Genetics · doi:10.1038/ng1161 · Cited by 2,985
Self-citationThe Metabolic Basis of Inherited Diseases
WINKELMANN, R. K. (1972) · Archives of Dermatology · doi:10.1001/archderm.1972.01620110090032 · Cited by 1,766
Apolipoprotein E Polymorphism and Cardiovascular Disease: A HuGE Review
Eichner, J. E. (2002) · American Journal of Epidemiology · doi:10.1093/aje/155.6.487 · Cited by 796
Weisgraber, K. H., Innerarity, T. L., & Mahley, R. W. (1982) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)34954-8 · Cited by 673
Apolipoprotein E structure: insights into function
Hatters, D. M., Peters-Libeu, C. A., & Weisgraber, K. H. (2006) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2006.06.008 · Cited by 583 · cited 3×
“Apo E distribution in each lipoprotein fraction showed a higher proportion in HDLs (77% vs. 63%– 69”
BackgroundInfluentialMahley, R. W., Huang, Y., & Rall, S. C. (1999) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)32417-2 · Cited by 447
Siest, G., Visvikis‐Siest, S., Herbeth, B., Gueguen, R., Vincent‐Viry, M., Sass, C., Beaud, B., Lecomte, E., Steinmetz, J., Locuty, J., et al. (1998) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.1998.007 · Cited by 140
Molecular spectrum of autosomal dominant hypercholesterolemia in France
Marduel, M., Carrié, A., Sassolas, A., Devillers, M., Carreau, V., Di Filippo, M., Erlich, D., Abifadel, M., Marques-Pinheiro, A., Munnich, A., et al. (2010) · Human Mutation · doi:10.1002/humu.21348 · Cited by 115
Self-citationCiveira, F., Jarauta, E., Cenarro, A., García-Otín, A. L., Tejedor, D., Zambón, D., Mallén, M., Ros, E., & Pocovı́, M. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.06.050 · Cited by 84
Solanas-Barca, M., de Castro-Orós, I., Mateo-Gallego, R., Cofán, M., Plana, N., Puzo, J., Burillo, E., Martín-Fuentes, P., Ros, E., Masana, L., et al. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2012.03.011 · Cited by 74
Research works printed but not linked: 1
- Mahley, 1989, The metabolic basis of inherited diseases, 1195
Cited by
Sorted by citations
Gidding, S. S., Ann Champagne, M., de Ferranti, S. D., Defesche, J., Ito, M. K., Knowles, J. W., McCrindle, B., Raal, F., Rader, D., Santos, R. D., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000297 · Cited by 723
Canuel, M., Sun, X., Asselin, M.-C., Paramithiotis, E., Prat, A., & Seidah, N. G. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064145 · Cited by 227
APOE gene variants in primary dyslipidemia
Khalil, Y. A., Rabès, J.-P., Boileau, C., & Varret, M. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.05.007 · Cited by 170
Self-citationGenetic and molecular architecture of familial hypercholesterolemia
Abifadel, M., & Boileau, C. (2022) · Journal of Internal Medicine · doi:10.1111/joim.13577 · Cited by 158
Self-citationLipidSeq: a next-generation clinical resequencing panel for monogenic dyslipidemias
Johansen, C. T., Dubé, J. B., Loyzer, M. N., MacDonald, A., Carter, D. E., McIntyre, A. D., Cao, H., Wang, J., Robinson, J. F., & Hegele, R. A. (2014) · Journal of Lipid Research · doi:10.1194/jlr.d045963 · Cited by 125
Metadata
- Authors
- Marduel, M., Ouguerram, K., Serre, V., Bonnefont-Rousselot, D., Marques-Pinheiro, A., Erik Berge, K., Devillers, M., Luc, G., Lecerf, J.-M., Tosolini, L., Erlich, D., Peloso, G. M., Stitziel, N., Nitchké, P., Jaïs, J.-P., The French Research Network on ADH, Abifadel, M., Kathiresan, S., Leren, T. P., Rabès, J.-P., Boileau, C., & Varret, M.
- Affiliations
- Inserm (FR)
- Medical Genetics Laboratory; Oslo University Hospital Rikshospitalet; Oslo; Norway
- Université de Lille (FR)
- Centre Hospitalier Universitaire de Lille (FR)
- Université Paris Denis Diderot; Paris; France
- Broad Institute (US)
- Hôpital Necker-Enfants Malades (FR)
- Oslo University Hospital (NO)
- Corresponding author
- Varret, Mathilde
- ORCID
- Venue
- Human Mutation
- Publisher
- Wiley
- Published
- 2012-10-11
- Volume
- 34
- Issue
- 1
- Pages
- 83-87
- ISSN
- 1059-7794 (ISSN-L)
- PMC
- PMC3638718
- OpenAlex
- W2072770085
- Semantic Scholar
- e4d31a1313c36bcd4d0998701fcdf0156fa0f973
- Cited by
- 133
- References
- 32
- Citations by year
- 2026: 7 · 2025: 7 · 2024: 10 · 2023: 9 · 2022: 11 · 2021: 9 · 2020: 6 · 2019: 9 · 2018: 12 · 2017: 12 · 2016: 9 · 2015: 7 · 2014: 14 · 2013: 10 · 2012: 1
- FWCI
- 10.45
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Human Mutation (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Agence Nationale de la Recherche (ANR-05-PCOD-0017, ANR-08-GENO-0002, ANR-06-MRAR-0038)
- National Heart, Lung, and Blood Institute (R01HL107816)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- autosomal dominant hypercholesterolemia, apolipoprotein E, familial hypercholesterolemia, LDL receptor, apolipoprotein B, PCSK9, type III hyperlipoproteinemia, LDL catabolism, family studies, exome sequencing, genome-wide mapping
- MeSH terms
- Adolescent, Adult, Apolipoproteins E, Child, Cholesterol, Chromosomes, Human, Pair 19, Family Health, Female, Haplotypes, Humans, Hyperlipoproteinemia Type II, Cholesterol, HDL, Cholesterol, LDL, Male, Middle Aged, Models, Molecular, Mutation, Pedigree, Triglycerides, Gene Deletion, Protein Structure, Secondary, Protein Structure, Tertiary, Genetic Predisposition to Disease, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-31, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-31 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
